<unk>  (developmental code name ALKS-5461) is a combination formulation of buprenorphine and<unk>  which is under development as an add on to antidepressants in treatment-resistant depression (TRD). ALKS-5461 failed to meet its primary efficacy endpoints in two trials from 2016. On the basis of a third study that did meet its primary endpoints, Alkermes initiated a rolling New Drug Application with the FDA. In November 2018, an FDA panel voted against recommending approval, finding that evidence was insufficient. As such, approval of the medication was rejected in 2019. It is a κ-opioid receptor (KOR) antagonist and is being developed by Alkermes.
Buprenorphine/samidorphan
Buprenorphine/naloxone
Buprenorphine/naltrexone
Oxycodone/naloxone
Fentanyl/fluanisone
Dextromethorphan/quinidine
Acetylmethadol
Phenylephrine/ketorolac